The drug regulator for the European Union effectively cleared Sanofi-Aventis diabetes drug Lantus from posing a greater risk of cancer, and said that the treatment should continue being prescribed and sold as usual.
The ruling was made by the European Medicines Agency earlier this week, and claimed that evidence linking the diabetic drug with cancer was inconclusive. Lantus is an insulin analogue that has been widely used since 2000.
The Committee for Medicinal Products for Human Use reportedly commented: “Following review of all available information on a possible relationship between insulin analogues … and the risk of cancer, the available data does not provide a cause for concern and that changes to the prescribing advice are, therefore, not necessary,” European Medicines Agency’s Committee for Medicinal Products for Human Use.”
Sanofi saw shares rise at the news, despite recent bad press in diabetes news.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…